GAITHERSBURG, Md., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the data from its Phase 2, MRI-based body composition sub-study of pemvidutide in subjects with overweight and obesity will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain. Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment o ...